NYSE$AGL

agilon health inc. · Q2 2021 earnings

Q2 2021 earnings · · Investor relations

Briefing

agilon health's second quarter results reflected continued momentum, with Medicare Advantage membership increasing 45% year-over-year and total members on the platform growing to over 280,000.

agilon health reported a 70% increase in total revenue to $499 million, driven by a 45% increase in Medicare Advantage membership. However, the company reported a net loss of $299 million, which includes $275 million in non-cash stock-based compensation expenses.

  • Total revenue increased 70% from 2020 to $499 million.
  • Medicare Advantage membership increased 45% from 2020.
  • Same geography membership growth was 17% from 2020.
  • Net loss was $299 million, including $275 million in non-cash stock-based compensation expenses.

Headline financials

Total Revenue

$499M

Previous: $294M+69.9%
EPS (adj)

-$0.79

Previous: -$0.02-3735.0%
Medicare Advantage Members

181.7K

Previous: 125.3K+45.0%
Avg. MA Members

194.0K

No prior period
Capital Expenditures

-$646K

No prior period
Free Cash Flow

-$299M

No prior period
Net Income

-$299M

Previous: -$7.91M-3677.6%
Operating Income

-$298M

Previous: -$1.25M-23730.9%
Cash & Equivalents

$1.11B

No prior period
Total Assets

$1.7B

No prior period

Revenue & EPS history

agilon health · Revenue · Quarterly

$499M

Q2 2021+69.9%vs Q2 2020
Beat estimate in 11 of 11 quarters(100%)
ActualEstimate

Revenue by segment

agilon health · $499M total across 2 segments · Q2 2021

  • Medical Services Revenue
    $498M+70.1%
  • Other Operating Revenue
    $1.28M+16.3%

Forward guidance

agilon health provided guidance for the third quarter and full year 2021. The company expects ending members to be between 183,000 and 184,000 for Q3 2021 and between 184,000 and 185,000 for the full year. Total revenues are expected to be between $450 million and $453 million for Q3 2021 and between $1.81 billion and $1.82 billion for the full year. Adjusted EBITDA is expected to be a loss between $41 million and $38 million for Q3 2021.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q2 2021

Historical avgQ2 2021

-2.6%

Avg return

Earnings day

-0.0%

Avg return

5 days after

+6.7%

Avg return

30 days after

50%

10 / 20 earnings

Positive

+20.2%

Q4 2025

Best reaction

-36.1%

Q3 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+4.2%+122.0%+256.9%
Q4 2025+20.2%+13.4%-20.8%
Q3 2025+5.1%-9.0%-9.9%
Q1 2025-25.6%-33.4%-51.6%
Q4 2024-7.4%-17.9%+23.7%
Q3 2024-36.1%-35.1%-24.7%
Q2 2024-12.7%-14.6%-36.8%
Q1 2024+7.5%+7.5%+40.8%
Q4 2023+3.1%-2.1%-1.1%
Q3 2023-13.1%-19.0%-33.1%
Q2 2023+0.7%+3.7%-7.9%
Q1 2023-3.4%-6.6%-18.9%
Q4 2022+15.4%+14.8%+12.0%
Q3 2022-12.7%-7.9%-8.6%
Q2 2022-3.3%-0.4%-20.3%
Q1 2022-8.6%-19.4%+1.3%
Q4 2021+10.6%+2.4%+31.7%
Q3 2021+2.7%+3.6%-9.5%
Q2 2021-3.8%-6.3%-3.4%
Q1 2021+6.3%+4.0%+14.0%
Q4 2020
Q3 2020
Q2 2020
Q1 2020
Q4 2019

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro